tailieunhanh - Bevacizumab versus PARP-inhibitors in women with newly diagnosed ovarian cancer: A network meta-analysis

In women with newly diagnosed ovarian cancer, bevacizumab and poly (ADP-ribose) polymerase inhibitors (PARPi) exhibit improved progression-free survival (PFS) when administered concurrent with chemotherapy and/or maintenance therapy, but no study has directly compared their effects. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN